Patents by Inventor Paul D. Crowe

Paul D. Crowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
    Publication number: 20020176866
    Abstract: The present invention is directed toward peptide analogs of human myelin basic protein. The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein. The analogs are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions Pharmaceutical compositions containing these peptide analogs are provided. The peptide analogs are useful for treating multiple sclerosis.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 28, 2002
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Amitabh Gaur, Paul Conlon, Nicholas C. Ling, Theophil Staehelin, Paul D. Crowe
  • Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
    Patent number: 6379670
    Abstract: The present invention is directed toward peptide analogs of human myelin basic protein. The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein. The analogs are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogs are provided. The peptide analogs are useful for treating multiple sclerosis.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: April 30, 2002
    Assignees: Neurocrine Biosciences, Inc., Novartis, AG
    Inventors: Amitabh Gaur, Paul Conlon, Nicholas C. Ling, Theophil Staehelin, Paul D. Crowe
  • Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
    Patent number: 6251396
    Abstract: The present invention is directed toward peptide analogs of human myelin basic protein. The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein. The analogs are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogs are provided. The peptide analogs are useful for treating multiple sclerosis.
    Type: Grant
    Filed: August 20, 1998
    Date of Patent: June 26, 2001
    Assignees: Neurocrine Biosciences, Inc., Novartis AG
    Inventors: Amitabh Gaur, Paul Conlon, Nicholas C. Ling, Theophil Staehelin, Paul D. Crowe